EquityZen Growth Technology Fund LLC - Series 2317 (CIK: 0002129065) EDGAR, Information, Filings... CompaniesBIO.Com

EquityZen Growth Technology Fund LLC - Series 2317

Mailing address
1 NEW YORK PLAZA, 12TH FLOOR, NEW YORK, Delaware, 10004
Phone
8774906121
State location
New York
State of incorporation
Delaware
Fiscal year end
December 31
SIC
N/A
Filings
N/A

EquityZen Growth Technology Fund LLC - Series 2317 (CIK: 0002129065) is an American company incorporated in the state of New York. Head office is located at 1 NEW YORK PLAZA, 12TH FLOOR, NEW YORK, New York, 10004. Work in the industry N/A. EquityZen Growth Technology Fund LLC - Series 2317 is a public company and trade via Over-The-Counter (OTC).

Includes all SEC registration details as well as a list of all documents (S-1, Prospectus, Current Reports, 8-K, 10K, Annual Reports) filed by EquityZen Growth Technology Fund LLC - Series 2317

Filings	Format	Description	Filed/Effective	File/Film Number
D	Document	Acc-no: 0002129065-26-000001 (33 Act) Size: KB	Jun-11-2026	021-587009 261082199

Recent 20 filings. View all EquityZen Growth Technology Fund LLC - Series 2317 filings

Overall rating 5.0

Aug 22, 2022

Catherine

Thanks I look forward to using the product to improve my skin tone

Aug 22, 2022

Jean Bishop

Very good communication and delivery made within the timeframe I was advised of

Aug 22, 2022

Samuel Ejimofor

It's being easier working on the website. And I recommend, it's a great website

EquityZen Growth Technology Fund LLC - Series 2317 overview
EquityZen Growth Technology Fund LLC - Series 2317 job
EquityZen Growth Technology Fund LLC - Series 2317 stock
EquityZen Growth Technology Fund LLC - Series 2317 ownership
EquityZen Growth Technology Fund LLC - Series 2317 CEO
EquityZen Growth Technology Fund LLC - Series 2317 documents

Disclaimer: The information on the Service is provided with the understanding that the Company is not herein engaged in rendering legal, accounting, tax, or other professional advice and services. As such, it should not be used as a substitute for consultation with professional accounting, tax, legal or other competent advisers.